Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Novartis pulls out of NASH partnership

<< Previous

Bullboard Posts

Next >>

Comment by SABBOBCATon Feb 24, 2023 11:37am

88 Views

Post# 35303478

RE:RE:RE:Novartis pulls out of NASH partnership

They are refocusing the business, but still need a robust pipeline. I my read through is they want to pare back risk, focus on core competencies, and drive revenue growth. So for the pipeline, this means focus on later stages of development vs preclinical. With the exception of Trogarzo (which TH doesn't own the IP), TH's assets fit with Novartis' focus areas and also fit the thereputic targets they are looking for.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec